A method for the treatment of primary hypertension

 

(57) Abstract:

The invention relates to medicine, namely cardiology, and can be used for the treatment of primary hypertension. On the background of chronic administration of angiotensin-converting enzyme inhibitor additionally take antioxidant. As an antioxidant accept-tocopherol acetate in three courses over the month. An interval of 4 to 5 months. The method allows to increase the sensitivity to antihypertensive agent. This increases the effectiveness of the treatment. 1 C.p. f-crystals.

The invention relates to medicine, namely cardiology, and can be used for the treatment of primary hypertension (PAG).

There is a method of treatment of primary hypertension - hypertension (see Zonov About A. Oxygen supply to tissues, microcirculation, lipid peroxidation in patients with essential hypertension and drug correction of the revealed infringements// abstract. Diss. Kida. the honey. Sciences. - Sverdlovsk, 1991 - 20 C.), consisting in a joint application within 3 weeks of the calcium antagonist nifedipine and antioxidants (a-tocopherol acetate, wazikashi - MC, lipid metabolism, the level of lipid peroxidation - FLOOR, increases the sensitivity to antihypertensive drug (nifedipine).

The disadvantage of this method is the short time of observation, which does not allow to detect changes of intracardiac hemodynamics.

There is a method of treatment of PAG, which contains the application within 3 weeks of angiotensin-converting enzyme inhibitor (ACEI) enalapril in treatment of hypertension (see Maslova, N. P., Lebedev, E. C., Baranov, E. I., Karpov A. P. Influence of treatment Enap on the performance of Central and intracardiac hemodynamics in patients with essential hypertension // Actual problems of modern echocardiography: proceedings of the II International Symposium "Clinical echocardiography" - St. Petersburg, 30-31 may 1996 - S. 61-63). The known method, taken as a prototype, helps to normalize the blood pressure, lower total peripheral vascular resistance.

The disadvantage of this method is the lack of significant influence on the performance of intracardiac hemodynamics - ejection fraction (EF), volume and dimensions of the left ventricle (LV).

The essence of the invention lies in the fact that simplebrowser enzyme, additionally apply an antioxidant, while taking antioxidant produced on the background of chronic administration of angiotensin-converting enzyme inhibitor in three courses over the month, with an interval between courses of 4-5 months. In addition, as an antioxidant used-tocopherol acetate.

Application of the proposed method allows to normalize HELL, the state of the MC, GENDER, improve sensitivity to antihypertensive agent, as well as the results of loading tests improves the portability of sick physical activity, according to echocardiography (EchoCG) improves intracardiac hemodynamics increases ejection fraction and reduces end-diastolic dimension LV, decreases the weight of the myocardium, improves the health of patients at 5-7 days of therapy (reduction in headache, recovery sleep), reduces symptoms of the metabolic syndrome (destabilization of cell membranes, hyperlipidemia, hyperglycemia), reduces the number of complications PAG (hypertensive crises, coronary artery disease, heart rhythm disturbances) and reduces the incidence of hospitalizations of patients.

The claimed method is as follows.

Patients with primary arterial hypertensia - enalapril maleate (in the first 30 days of observation at a daily dose of 20 to 30 mg, and then in supporting individual doses of 5 - 20 mg), additionally, get therapy, antioxidant (vitamin E) courses for 30 days (courses 4-5 months) in a daily dose of 600 mg.

Examples of specific performance.

Example 1. Patient A., 48 years old, was admitted to the hospital with a diagnosis of primary hypertension, reasonable shape, moderately progressive course. H II A.

Upon receipt bothered pressing pain in the occipital region, insomnia, mood lability, stabbing pain in the heart and shortness of breath on mild exertion. Hypertensive crises to 2-4 times per month.

Objectively: the state closer to satisfactory. Moderate cyanosis, redness of the sclera. The vesicular breathing hard. Borders of the heart: left - 1 cm outwards from the mid-clavicle line, right, top - normal. Heart sounds rhythmic, I tone II tone. HELL 180/110 mm RT.article.

Lab: lipid peroxidation 276 imp./(N 160), the stability of the membrane (CM) 94 (N more than 120), cholesterol (LDL) 6.2 mmol/l, glucose 6.2 mmol/l, triglycerides (TG) 3.2 mmol/L.

Integral rheography of the body (IRGT): stroke volume (PP) 65 ml, the opposition (oops) 4700 dissm-5; Echocardiography: left atrium (PL) 35 mm, end-diastolic dimension LV (CRA) 58 mm, end-diastolic volume (BWW) 195 ml, end-systolic dimension (DAC) 39 mm, end-systolic volume (CSR) 59 ml, ejection fraction (EF) of 69%. Interventricular septum (MoHSP) 11 mm, the thickness of the posterior wall of the left ventricle (TCS) 12 mm Weight infarction (MM) 326 mg

According to rheoencephalography (REG): enhancement of vascular tone, signs of venous hyperemia, a decrease in the amplitude of pulse blood.

The patient received enalapril daily dose of 20 mg for 12 months and a-tocopherol acetate 600 mg per day orally 3 courses for 30 days.

After 30 days, noted the absence of headache, recovery sleep, improved mood. The blood pressure has stabilized (up to 140/80 mm RT. Art.), heart rate 76 min Echocardiography: PL=35 mm, LV KDR=57 mm, BWW=185 ml, DAC=38 mm, CSR=55 ml, PV=70%, annuals=11 mm, TCS=12 mm, MM=326 mg

After 12 months of treatment: AD = 130/80 mm RT. senior Health is satisfactory, crises were noted. Improved sleep. The mood is smooth. Increased efficiency. Almost not bother shortness of breath. Exact: PL=34 mm, LV KDR= 54 mm, BWW=157 ml, DAC=36 mm, CSR=46 ml, PV=70%, annuals=10 mm, TCS=11 mm, MM= 262 mg. IGG: UO= 70 ml, IOC= 4.9 litres/minm2, C=1.9 l/min, oops=2700 di is">

REG no specifics.

Example 2. Patient B., aged 52, was admitted to the hospital with a diagnosis of primary hypertension, stage II, severe, moderate, progressive course. H II A.

Upon receipt bothered severe headaches in the occipital region during the whole day, more in the evening, fatigue, decreased performance, decreased urine output within 3-5 days, and pain in the heart when raising HELL, a disruption of the heart, shortness of breath when walking up to 300 meters

Objectively: the state closer to satisfactory. Moderate power, normostenik. Skin warm, mild cyanosis of the lips. The vesicular breathing hard. NPV=21. Borders of the heart: the left is increased by 2 see the Colours of hearts I > II, arrhythmic (up to 2-3 PVCs / min), heart rate of 72 per minute, HELL 210/120 mm RT. Art.

The patient is assigned to amlodipine at a dose of 30 mg per day (20 mg in the morning and 10 mg in the evening) and a-tocopherol at a dose of 600 mg per day within 30 days.

Tests: complete blood count and complete urine analysis without features, XC 6.2 mmol/l, TG 2.6 mmol/l, glucose of 6.1 mmol/l; FLOOR 312 imp./C; CM 102 C. a Sample of zimnitsky tests without features. Sample Rehberg - reduction of glomerular filtration rate to 87%. Ultrasound of the kidneys - without features.

EARTH: SI 1.3 ml/min, PP 65 ml, IOC 4.2 l/minm2.

Echocardiography: LV DAC 42 mm, the CRA 59 mm, CSR 74 ml, MLC 205 ml, PHI 63%, annuals 10 mm, TCS 12 mm, MM 325 mg Radiography of the chest: an increase in LV. Signs of stagnation in a small circle.

After 30 days of therapy being improved, headaches, worry less, improved mood, recovered diuresis. Almost no pain in her heart, no interruptions. Increased tolerance to physical loads.

Objectively: the patient is in satisfactory condition. Remains easy cyanosis of the lips. The vesicular breathing, without adverse respiratory noise. NPV 18 in minutes heart sounds rhythmic, I > II, 72 HR, min, BP 150/90 mm RT. senior Analyses without changes.

After 12 months of treatment with enalapril and again in 4-5 months, courses-tocopherol being satisfactory. Objective: HELL 140/80 mm RT. senior HR 70 minutes Tests: complete blood count and urine without features, XC 5.3 mmol/l, triglycerides 1.7 mmol/l, glucose of 5.4 mmol/l, FLOOR 154 imp. /sec. CM 217 S. Microcirculation: decreased effects of perivascular edema and spasm of the arterioles.

REG: remain signs of venous hyperemia.

the primary arterial hypertension, include the use of angiotensin-converting enzyme inhibitor, characterized in that it further apply an antioxidant, while taking antioxidant produced on the background of chronic administration of angiotensin-converting enzyme inhibitor in three courses over the month, with an interval between courses of 4-5 months.

2. The method according to p. 1, characterized in that the antioxidant is used-tocopherol acetate.

 

Same patents:

The invention relates to medicine, namely cardiology, and for the treatment of hypertension
The invention relates to medicine, more specifically to pulmonology, and can be used for the prevention of pulmonary hypertension in patients with chronic obstructive lung disease

The invention relates to new substituted 4-(1,2,3,4-tetrahydro-1-naphthalenyl)-1H-imidazoles and 4-(2,3-dihydro-1H-inden-1-yl)-1H-imidazoles and their additive salts, to processes for their preparation and to pharmaceutical compositions based on them

The invention relates to new 3-intellipedia formula I, where R1, R2, R3and R4denote H, A, OH, OA, F, Cl, Br, J, CN, CF3, COOH, CONH2, CONHA, CONA2or COOA, or R1and R2and R3and R4together denote methylenedioxy, R5Is H or OH, R6- H or R5and R6together denote a bond, And represents C1- C6-alkyl, n denotes a number from 2 to 6, and their physiologically acceptable salts

The invention relates to the field of medicine and is suitable for the treatment of acute and chronic coronary insufficiency, stable and unstable angina, supraventricular tachycardia and arrhythmia, arterial hypertension and hypertensive crisis

The invention relates to medicine, and more specifically to the photosensitizers for photodynamic therapy (PDT) of malignant tumors and other abnormal growths

The invention relates to pharmaceutical dosage forms darifenacin and its pharmaceutically acceptable salts

The invention relates to substituted imidazolidin-2,4-donovin compounds, method of their production and to the use of these compounds in medicine

The invention relates to new cyclic amine derivatives of General formula I, where R1represents a phenyl group substituted by halogen atom,2represents C1- C8aliphatic acyl group or (C1- C4alkoxy)carbonyl group, R3represents a 3 - to 7-membered saturated cyclic amino group which may form a condensed ring, where the specified cyclic amino group substituted by the Deputy selected from the group comprising: mercaptopropyl, which can be unprotected or protected by a group selected from a number of protective groups, C1- C4alkyl group, substituted mercaptopropyl, which can be unprotected or protected by a group selected from a number of protective groups, and the number of protective groups for the specified mercaptopropyl includes C1- C20alcoholnye group, C3- C20alkenone group and benzoline group, and the said cyclic amino group, furthermore preferably a substituted group of the formula =CR4R5where R4represents a hydrogen atom, and R5represents a hydrogen atom, a C1- C4alkyl group, carboxypropyl, (C1- C4-alkoxy)carbonyl GRU

The invention relates to 1-(21oksifenil)-2-methylpyrrole that exhibits antimicrobial activity and may find application in medicine as an antimicrobial agent in the local destination

The invention relates to derivatives of 2-phenylindole, mixtures of their isomers or individual isomers of General formula I, where R1is unbranched or branched C1-C8is alkyl or hydrogen; R2- the remainder of the formula CO-NH2or-CH2-OH

The invention relates to 1H-indol-3-acetamide General formula I where X is oxygen; R1selected from groups (i), (iii), where (i)6-C20-alkyl, C4-C12-cycloalkyl; (iii) - (CH2)n-(R80), where n is 1-8 and R80is the group specified in (i); R2is hydrogen, halogen, C1-C3-alkyl, C1-C2-alkylthio,1-C2-alkoxy; R3each independently is hydrogen or methyl; R4- R7each independently - C1-C10-alkyl, C2-C10alkenyl,3-C8-cycloalkyl,1-C10-alkoxy,

WITH4-C8-cycloalkane, phenoxy, halogen, hydroxy, carboxyl, -C(O)O(C1-C10-alkyl), hydrazide, hydrazino, NH2, NO2, -C(O)NR82R83where R82and R83independently is hydrogen, C1-C10-alkyl or a group of formula (a), where R84and R85independently is hydrogen, C1-C10-alkyl; p= 1 to 5; z is a bond, -O-, -NH-; Q is-CON(R82R83), -SO3H, phenyl, a group of formula b), C), (d), where R86independently selected from hydrogen, C1-C10-alkyl, and their pharmaceutically acceptable salts or their esters, or Amida
The invention relates to an improved form of drug-candle
Up!